Insider Selling: Biodesix, Inc. (NASDAQ:BDSX) CFO Sells 24,664 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) CFO Robin Harper Cowie sold 24,664 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $22,690.88. Following the completion of the sale, the chief financial officer now owns 246,460 shares of the company’s stock, valued at approximately $226,743.20. This trade represents a 9.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Biodesix Trading Down 1.1 %

Biodesix stock opened at $0.94 on Thursday. The stock has a 50-day moving average of $1.25 and a two-hundred day moving average of $1.49. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. Biodesix, Inc. has a one year low of $0.86 and a one year high of $2.04. The stock has a market cap of $136.74 million, a PE ratio of -2.41 and a beta of 1.06.

Institutional Investors Weigh In On Biodesix

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BDSX. Perkins Capital Management Inc. raised its stake in Biodesix by 74.7% in the third quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after buying an additional 310,000 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Biodesix in the third quarter valued at about $262,000. Barclays PLC raised its stake in shares of Biodesix by 1,140.5% in the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock worth $41,000 after purchasing an additional 21,179 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Biodesix by 50.7% in the third quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock worth $1,433,000 after purchasing an additional 270,724 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Biodesix in the third quarter worth about $10,849,000. 20.96% of the stock is currently owned by hedge funds and other institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.